BEAM Share Price Performance
US$0
-16.01 (-100.00%)
Price US$0
Fair ValueUS$150.00
Share Pricen/a
Analysis Article • Aug 10
Beam Therapeutics Inc. Stock Price
- 4 Narratives written by author
- 2 Comments on narratives written by author
- 145 Fair Values set on narratives written by author
BEAM Community Narratives
DA
Fair Value
·Fair Value US$150 80.2% undervalued intrinsic discount
The "Molecular Pencil": Why Beam's Technology is Built to Win
13users have liked this narrative
2users have commented on this narrative
75users have followed this narrative
AN
Fair Value
·Fair Value US$51.07 41.7% undervalued intrinsic discount
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
0users have liked this narrative
0users have commented on this narrative
57users have followed this narrative
AN
Fair Value
·Fair Value US$26 14.5% overvalued intrinsic discount
Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
The "Molecular Pencil": Why Beam's Technology is Built to Win
Beam Therapeutics is betting that a newer, more precise form of gene editing can fix genetic diseases without the DNA damage risks tied to older approaches. Early human results in a liver-targeted program, plus a push to remove harsh chemotherapy from stem cell transplants, could open much larger patient groups—but competition and clinical execution still matter.Read more
DA
US$150
80.2% undervalued intrinsic discount
Fair Value
Profit Margin
21.34%
Future PE
30.21x
Price in 2028
US$183.38
Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway
Beam Therapeutics is betting that its gene-editing approach can become a repeatable “platform” used across several serious diseases, but that only works if real-world manufacturing, clinical results, and regulators all move faster than expected. If those pieces don’t line up, the company could spend heavily for years without the kind of treatment launches needed to justify today’s optimism.Read more
AN
US$26
14.5% overvalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
506.39x
Price in 2029
US$32
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Beam Therapeutics is pushing two experimental gene-editing treatments for blood and liver diseases that could widen who can be treated and make its approach stand out. But safety concerns tied to the chemotherapy used today, plus tough competition and long approval timelines, could slow progress.Read more
AN
US$51.07
41.7% undervalued intrinsic discount
Fair Value
Profit Margin
18.98%
Future PE
164.88x
Price in 2029
US$62.73
Liver Base Editing Platform Will Transform Rare Disease Treatment Over The Long Term
Catalysts About Beam Therapeutics Beam Therapeutics focuses on base editing therapies aimed at providing onetime genetic treatments for serious diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
US$80
62.8% undervalued intrinsic discount
Fair Value
Profit Margin
10.54%
Future PE
361.75x
Price in 2029
US$98.48
Trending Discussion
No trending discussion available.
Recently Updated Narratives
DA
Next Milestones For Beam in 2026.
Fair Value: US$150 80.2% undervalued intrinsic discount
75 fair values setusers have set this as their fair value
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BEAM: Strong Gene Editing Pipeline Will Likely Fail To Justify Current Hype
Fair Value: US$26 14.5% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BEAM: Positive Gene Editing Data And Regulatory Tailwinds Will Drive Future Repricing
Fair Value: US$51.07 41.7% undervalued intrinsic discount
57 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Beam Therapeutics Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.87
- -161.91%
- -55.45%
- 9.4%
About BEAM
- Founded
- 2017
- Employees
- 540
- CEO
- WebsiteView website
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
